Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 9/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 5/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30241905 | 1.00 | SLC22A12 (0.56) | SLC22A12METRPS6KA5PARP1RPS6KA4 | |
| SCHEMBL30532842 | 0.98 | SLC22A12 (0.55) | SLC22A12METRPS6KA5PARP1RPS6KA4 | |
| SCHEMBL14312991 | 0.87 | PARP1 (0.56) | SLC22A12METRPS6KA5PARP1RPS6KA4 | |
| SCHEMBL31200457 | 0.84 | SLC22A12 (0.55) | SLC22A12METRPS6KA5PARP1RPS6KA4 | |
| SCHEMBL4714519 | 0.83 | SLC22A12 (0.66) | SLC22A12METRPS6KA5SMN1; SMN2 | |
| SCHEMBL759396 | 0.76 | SLC22A12 (0.48) | SLC22A12METRPS6KA5RAPGEF4 | |
| SCHEMBL29962730 | 0.76 | SLC22A12 (0.48) | SLC22A12METRPS6KA5RAPGEF4 | |
| SCHEMBL857765 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2 | |
| SCHEMBL5803359 | 0.73 | SLC22A12 (0.45) | SLC22A12METRPS6KA5RPS6KA4CDC7 | |
| SCHEMBL29898292 | 0.73 | SLC22A12 (1.00) | SLC22A12METRPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240124493-A1 | Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| WO-2023230541-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-116731016-A | Tricyclic heterocyclic compounds as IAP antagonists | 苏州亚盛药业有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| CN-109803971-B | Monocyclic and bicyclic substituted carbanucleoside analogs as PRMT5 inhibitors | 詹森药业有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-05-24 | — | — | US | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3728252-A1 | 4-AZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-104011050-A | 2, 4-diamino-pyrimidine derivatives as serine/threonine kinase inhibitors | HOFFMANN LA ROCHE | 2014-08-27 | — | — | CN | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| EP-2342202-A1 | AZAINDOLE DERIVATIVE | Merck Patent GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| WO-2010046013-A1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
| CN-1244798-A | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | RHONE POULENC RORER PHARMA (US) | 2000-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | SLC22A12 3271/4885MET 2938/4885RPS6KA5 543/4885 |
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | SLC22A12 618/4885MET 555/4885RPS6KA5 1934/4885 |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | AHR, ARNT, AIPL1 | SLC22A12 3925/4885MET 491/4885RPS6KA5 2590/4885 |
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | BAX, LITAF, PNLIP | SLC22A12 3370/4885MET 3056/4885RPS6KA5 764/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | SLC22A12 1054/4885MET 924/4885RPS6KA5 1884/4885 |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | SLC22A12 1804/4885MET 4158/4885RPS6KA5 2307/4885 |
| US-20240124493-A1 | Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | SLC22A12 3896/4885MET 2519/4885RPS6KA5 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.